Evidence base — read this first
Part of a family of short synthetic peptides (2-4 amino acids) developed by Vladimir Khavinson's research group, each targeted at a specific tissue/organ. The evidence base for this entire peptide family shares the same limitation: it's concentrated almost entirely within this one research lineage (largely the same institute, often the same handful of authors), is mostly preclinical (rodent, cell-culture) or small Russian human pilot work, and hasn't been independently replicated by unaffiliated Western labs in a way this research pass could verify. None of these compounds is FDA or EMA approved for human use anywhere.
Benefits
Cartalax (Ala-Glu-Asp) is pitched as a cartilage/connective-tissue peptide, with secondary reporting describing effects on fibroblast proliferation and SIRT6 expression — these specific claims weren't independently verified against a primary source in this research pass.
What does this actually target?+
Cartilage and joint tissue specifically — part of the same Khavinson bioregulator family as Cardiogen, Bronchogen, and the others, each a very short peptide aimed at one organ's own regulatory signaling.
How is this actually dosed?+
Same pattern as the rest of the family — a short course, roughly 10-20 days, repeated once or twice a year rather than continuous daily use.
Looking for something specific, or placing a wholesale order? Send us a DM or email.